In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
To read the full story
Related Article
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
April 15, 2021
- Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
REGULATORY
- MHLW Panel Sorts Out Challenges for Stable Supply of Plasma-Derived Products
December 24, 2024
- Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
- CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
- Opposition Parties Submit Bill to Scrap Off-Year Drug Price Revisions
December 23, 2024
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…